Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H21NO.C6H8O7 |
Molecular Weight | 447.4783 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC(O)(CC(O)=O)C(O)=O.CN(C)CCOC1=C(CC2=CC=CC=C2)C=CC=C1
InChI
InChIKey=ZZYHCCDMBJTROG-UHFFFAOYSA-N
InChI=1S/C17H21NO.C6H8O7/c1-18(2)12-13-19-17-11-7-6-10-16(17)14-15-8-4-3-5-9-15;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-11H,12-14H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
Molecular Formula | C6H8O7 |
Molecular Weight | 192.1235 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C17H21NO |
Molecular Weight | 255.3547 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Phenyltoloxamine is an ethanolamine derivative with antihistaminic property, which is used in combination with some analgesics for the temporary relief of minor aches and pains associated with headache; backache; muscular aches; temporarily reduces fever and some others disorders. Phenyltoloxamine blocks H1 histamine receptor, thereby inhibiting phospholipase A2 and production of endothelium-derived relaxing factor, nitric oxide. Subsequent lack of activation of guanylyl cyclase through nitric oxide results in decreased cyclic GMP levels, thereby inhibiting smooth muscle constriction of various tissues, decreasing capillary permeability and decreasing other histamine-activated allergic reactions.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8227466 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Bristalin Approved UsePhenyltoloxamine is a first generation antihistamine that is used for symptoms of the common cold and as a short acting sedative. Launch Date1951 |
|||
Primary | DOLOGESIC Approved UseUnknown |
|||
Palliative | DOLOGESIC Approved UseUnknown |
|||
Palliative | DOLOGESIC Approved UseUnknown |
|||
Palliative | DOLOGESIC Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
[Antimycobacterial antihistaminics]. | 1989 Aug |
|
Drugs associated with more suicidal ideations are also associated with more suicide attempts. | 2009 Oct 2 |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Patents
Sample Use Guides
adults and children 12 years of age and older: take 1 or 2 tablespoons of DOLOGESIC (acetaminophen, phenyltoloxamine citrate, alcohol liquid); every 4 to 6 hours.
children under 12 years of age: Consult a physician; do not give this product to children under 12 years of age. This product will provide more than the recommended dose (overdose) of non-aspirin and could cause serious health problems
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:18:18 GMT 2023
by
admin
on
Fri Dec 15 16:18:18 GMT 2023
|
Record UNII |
8UE48MJH8M
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 16:18:18 GMT 2023 , Edited by admin on Fri Dec 15 16:18:18 GMT 2023
|
||
|
CFR |
21 CFR 310.201
Created by
admin on Fri Dec 15 16:18:18 GMT 2023 , Edited by admin on Fri Dec 15 16:18:18 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
8UE48MJH8M
Created by
admin on Fri Dec 15 16:18:18 GMT 2023 , Edited by admin on Fri Dec 15 16:18:18 GMT 2023
|
PRIMARY | |||
|
14440
Created by
admin on Fri Dec 15 16:18:18 GMT 2023 , Edited by admin on Fri Dec 15 16:18:18 GMT 2023
|
PRIMARY | |||
|
100000085281
Created by
admin on Fri Dec 15 16:18:18 GMT 2023 , Edited by admin on Fri Dec 15 16:18:18 GMT 2023
|
PRIMARY | |||
|
1534402
Created by
admin on Fri Dec 15 16:18:18 GMT 2023 , Edited by admin on Fri Dec 15 16:18:18 GMT 2023
|
PRIMARY | |||
|
214-644-7
Created by
admin on Fri Dec 15 16:18:18 GMT 2023 , Edited by admin on Fri Dec 15 16:18:18 GMT 2023
|
PRIMARY | |||
|
1176-08-5
Created by
admin on Fri Dec 15 16:18:18 GMT 2023 , Edited by admin on Fri Dec 15 16:18:18 GMT 2023
|
PRIMARY | |||
|
DBSALT001531
Created by
admin on Fri Dec 15 16:18:18 GMT 2023 , Edited by admin on Fri Dec 15 16:18:18 GMT 2023
|
PRIMARY | |||
|
169860
Created by
admin on Fri Dec 15 16:18:18 GMT 2023 , Edited by admin on Fri Dec 15 16:18:18 GMT 2023
|
PRIMARY | |||
|
DTXSID5047790
Created by
admin on Fri Dec 15 16:18:18 GMT 2023 , Edited by admin on Fri Dec 15 16:18:18 GMT 2023
|
PRIMARY | |||
|
8UE48MJH8M
Created by
admin on Fri Dec 15 16:18:18 GMT 2023 , Edited by admin on Fri Dec 15 16:18:18 GMT 2023
|
PRIMARY | |||
|
221141
Created by
admin on Fri Dec 15 16:18:18 GMT 2023 , Edited by admin on Fri Dec 15 16:18:18 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB03784MIG
Created by
admin on Fri Dec 15 16:18:18 GMT 2023 , Edited by admin on Fri Dec 15 16:18:18 GMT 2023
|
PRIMARY | |||
|
C82275
Created by
admin on Fri Dec 15 16:18:18 GMT 2023 , Edited by admin on Fri Dec 15 16:18:18 GMT 2023
|
PRIMARY | |||
|
m8695
Created by
admin on Fri Dec 15 16:18:18 GMT 2023 , Edited by admin on Fri Dec 15 16:18:18 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL186720
Created by
admin on Fri Dec 15 16:18:18 GMT 2023 , Edited by admin on Fri Dec 15 16:18:18 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |